牛牛AI助理已提取核心訊息
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.
Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.
總部位於特拉華州的生物技術公司Evelo Biosciences, Inc. 已於2024年1月26日向美國證券交易委員會（SEC）提交了生效後第1號修正案，要求註銷先前根據S-3表格註冊聲明註冊的所有未售出普通股。該行動是在公司董事會於2023年11月21日決定根據《特拉華州通用公司法》解散公司並尋求股東批准解散之後採取的。董事會認爲解散符合公司及其利益相關者的最大利益。提交生效後修正案是終止註冊聲明的有效性並從註冊中刪除任何未售出證券的正式步驟，實際上終止了根據這些聲明發行的證券。
總部位於特拉華州的生物技術公司Evelo Biosciences, Inc. 已於2024年1月26日向美國證券交易委員會（SEC）提交了生效後第1號修正案，要求註銷先前根據S-3表格註冊聲明註冊的所有未售出普通股。該行動是在公司董事會於2023年11月21日決定根據《特拉華州通用公司法》解散公司並尋求股東批准解散之後採取的。董事會認爲解散符合公司及其利益相關者的最大利益。提交生效後修正案是終止註冊聲明的有效性並從註冊中刪除任何未售出證券的正式步驟，實際上終止了根據這些聲明發行的證券。
有用
沒用
該公告為獨立文件：